ATE557102T1 - Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit - Google Patents

Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit

Info

Publication number
ATE557102T1
ATE557102T1 AT10003542T AT10003542T ATE557102T1 AT E557102 T1 ATE557102 T1 AT E557102T1 AT 10003542 T AT10003542 T AT 10003542T AT 10003542 T AT10003542 T AT 10003542T AT E557102 T1 ATE557102 T1 AT E557102T1
Authority
AT
Austria
Prior art keywords
methods
diagnosing
multiple sclerosis
predicting
effectiveness
Prior art date
Application number
AT10003542T
Other languages
English (en)
Inventor
Frank Weber
Bertram Mueller-Myhsok
Manfred Uhr
Susanne Lucae
Daria Salyakina
Florian Holsboer
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE557102T1 publication Critical patent/ATE557102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT10003542T 2006-02-27 2007-02-27 Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit ATE557102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06003978A EP1826277A1 (de) 2006-02-27 2006-02-27 Methoden zur Vorhersage der Wirksamkeit von Interferon Therapie bei Multiple Sklerose Patienten und Methoden zur Diagnose der Krankheit

Publications (1)

Publication Number Publication Date
ATE557102T1 true ATE557102T1 (de) 2012-05-15

Family

ID=36658688

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07711702T ATE466959T1 (de) 2006-02-27 2007-02-27 Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose
AT10003542T ATE557102T1 (de) 2006-02-27 2007-02-27 Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07711702T ATE466959T1 (de) 2006-02-27 2007-02-27 Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose

Country Status (7)

Country Link
US (1) US8071299B2 (de)
EP (4) EP1826277A1 (de)
AT (2) ATE466959T1 (de)
DE (1) DE602007006284D1 (de)
DK (2) DK1991696T3 (de)
SI (1) SI2196545T1 (de)
WO (1) WO2007096197A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207902A1 (de) * 2007-11-09 2010-07-21 INSERM (Institut National de la Santé et de la Recherche Medicale) Verfahren zur vorhersage der therapeutischen ansprechbarkeit von patienten auf eine medizinische behandlung mit einem interferon
AU2009273277A1 (en) * 2008-07-24 2010-01-28 Merck Serono S.A. Use of genetic markers for identifying the response to interferon treatment in Multiple Sclerosis patients
WO2011117267A1 (en) * 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2380992A1 (de) * 2010-04-21 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Vorhersage einer Antikörperreaktion auf eine Interferon-Therapie bei Patienten mit multipler Sklerose
WO2018140156A1 (en) * 2017-01-27 2018-08-02 Orig3N, Inc. Systems and methods for determining and presenting purchase recommendations based on personal genetic profiles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114998A3 (de) 1999-10-28 2001-08-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Verfahren zur Bestimmung von Erfolgsquote von Multiple Sklerose-Behandlung
WO2003014319A2 (en) 2001-08-07 2003-02-20 Genaissance Pharmaceuticals, Inc. Polymorphisms associated with multiple sclerosis
SE0103423D0 (sv) 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
GB0307914D0 (en) 2003-04-07 2003-05-14 Univ Dundee Cytochrome p450
EP1706507A4 (de) * 2003-11-26 2008-02-20 Univ Ohio State Res Found Das risiko und die progression von multipler sklerose vorhersagenden polymorphen cd24-genotypen

Also Published As

Publication number Publication date
DE602007006284D1 (de) 2010-06-17
WO2007096197A3 (en) 2007-10-18
EP1826277A1 (de) 2007-08-29
US8071299B2 (en) 2011-12-06
DK1991696T3 (da) 2010-08-30
DK2196545T3 (da) 2012-07-16
EP2196546B1 (de) 2013-02-27
WO2007096197A2 (en) 2007-08-30
EP2196546A1 (de) 2010-06-16
EP2196545A1 (de) 2010-06-16
SI2196545T1 (sl) 2012-09-28
ATE466959T1 (de) 2010-05-15
US20090186773A1 (en) 2009-07-23
EP1991696A2 (de) 2008-11-19
EP1991696B1 (de) 2010-05-05
EP2196545B1 (de) 2012-05-09

Similar Documents

Publication Publication Date Title
ATE413902T1 (de) Patientenüberwachungssystem
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
ATE557102T1 (de) Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
DK1715890T3 (da) CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EP2287340A3 (de) Verfahren zur Diagnose und Behandlung einer Geisteskrankheit
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ATE478335T1 (de) Verfahren in echtzeit zur erkennung von akuten entzündungszuständen
WO2007087646A3 (en) Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE551067T1 (de) Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
DE602006018145D1 (de) Verfahren zur diagnose und behandlung auf nr2-peptiden beruhender zerebrovaskulärer ereignisse
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
ATE534397T1 (de) Verwendung von dmbt1 zum einfangen von sulfat- und phosphatgruppen exponierenden agenzien